$HALB Halberd Corp’s (OTC: HALB) Groundbreaking
Post# of 630
(Total Views: 159)
Posted On: 07/24/2024 8:20:20 AM
$HALB Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results
https://www.globenewswire.com/en/news-release...sults.html
JACKSON CENTER, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC-PINK: "HALB”) has announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-Ax™ nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma.
Dr. Russell Carr, the project's Principal Investigator, commented: “In the early stages of our Phase II studies, we focused on assessing the efficacy of our innovative Tri-Ax™ nasal spray in producing positive outcomes when administered shortly after a TBI event. We included behavioral function as a key endpoint, which is significantly impacted by TBI.”
Dr. Carr elaborated, “Preliminary data reveal that higher impact forces lead to step-wise changes in motor activity levels. Notably, with one of the higher impact forces, TBI-induced motor activity changes were significantly improved when Tri-Ax™ was administered one hour post-impact. These findings suggest that the therapeutic benefits of Tri-Ax™ can be achieved when administered promptly after injury.”
William A. Hartman, Halberd's Chairman, President, and CEO, added, “We are optimistic that our successful Phase II testing will highlight the unique advantages of our patent-pending nasal spray in preventing neurodegeneration following head trauma. Potential applications for Halberd’s nasal spray include military and civilian contact sports, law enforcement, hospitals, and emergency response units dealing with automobile accidents and falls. The market potential for this product is substantial if ongoing tests continue to support our initial optimism.”
These results are very encouraging to point of injury (POI) care. Administration of this novel TBI therapeutic translates to the potential of buddy care or self-administration via a developing auto-nasal injector under development at Halberd’s partner Athena GTX.
https://www.globenewswire.com/en/news-release...sults.html
JACKSON CENTER, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC-PINK: "HALB”) has announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-Ax™ nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma.
Dr. Russell Carr, the project's Principal Investigator, commented: “In the early stages of our Phase II studies, we focused on assessing the efficacy of our innovative Tri-Ax™ nasal spray in producing positive outcomes when administered shortly after a TBI event. We included behavioral function as a key endpoint, which is significantly impacted by TBI.”
Dr. Carr elaborated, “Preliminary data reveal that higher impact forces lead to step-wise changes in motor activity levels. Notably, with one of the higher impact forces, TBI-induced motor activity changes were significantly improved when Tri-Ax™ was administered one hour post-impact. These findings suggest that the therapeutic benefits of Tri-Ax™ can be achieved when administered promptly after injury.”
William A. Hartman, Halberd's Chairman, President, and CEO, added, “We are optimistic that our successful Phase II testing will highlight the unique advantages of our patent-pending nasal spray in preventing neurodegeneration following head trauma. Potential applications for Halberd’s nasal spray include military and civilian contact sports, law enforcement, hospitals, and emergency response units dealing with automobile accidents and falls. The market potential for this product is substantial if ongoing tests continue to support our initial optimism.”
These results are very encouraging to point of injury (POI) care. Administration of this novel TBI therapeutic translates to the potential of buddy care or self-administration via a developing auto-nasal injector under development at Halberd’s partner Athena GTX.
(0)
(0)